Back to search
FDAFDA · Food and drugs·Recall number D-0877-2023

Glycopyrrolate Tablets, USP, 1 mg, 100-count bottles, Rx Only, Distributed by: Aurobindo Pharma USA, Inc., East Windsor, NJ 08520, NDC 13107-014-01

Published June 28, 2023 · Recall initiated: May 18, 2023

Summary

FDA records drug Class III recall D-0877-2023, published June 28, 2023 and initiated May 18, 2023. Recalling firm: Aurolife Pharma, LLC; Status: Terminated; Lot: Lot #: 01421038A1, Exp. Date 05/2023. Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Impurities/Degradation Specifications

Get an email if GLYCOPYRROLATE has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
GLYCOPYRROLATE
Manufacturer
Aurolife Pharma, LLC
Distributor
Nationwide within the United States
UPC
0313107014017
Lot
Lot #: 01421038A1, Exp. Date 05/2023
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Glycopyrrolate Tablets, USP, 1 mg, 100-count bottles, Rx Only, Distributed by: Aurobindo Pharma USA, Inc., East Windsor, NJ 08520, NDC 13107-014-01 recalled?

Yes. FDA published recall D-0877-2023 on June 28, 2023. Reported hazard: Failed Impurities/Degradation Specifications

What should I do if I have this product?

Stop using or selling the product and check the official FDA notice (D-0877-2023) for return or repair instructions.

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: GLYCOPYRROLATE. UPC: 0313107014017.